Related Experiment Video
Updated: May 6, 2026
Robot-assisted Total Mesorectal Excision and Lateral Pelvic Lymph Node Dissection for Locally Advanced Middle-low Rectal Cancer
Published on: February 12, 2022
Commentary on the "A multidisciplinary opioid-reduction pathway for robotic prostatectomy: outcomes at year one"
Binbin Zhu1,2, Angyang Cao3,4, Yijun Chen3
1Anesthesiology Department, The First Affiliated Hospital of Ningbo University, Ningbo, China. pingchi1983@126.com.
Background:
Opioid-sparing multimodal analgesia is increasingly emphasized for postoperative pain management. This commentary discusses a study by Manning et al. on an opioid reduction pathway for robotic prostatectomy.
Methods:
We reviewed the Manning et al. study, which implemented a multidisciplinary opioid reduction pathway and compared outcomes before and after pathway implementation. Outcomes included opioid use, pain scores, antiemetic use, length of stay, and readmissions.
Results:
The study found reduced opioid consumption, lower antiemetic use, shorter length of stay, and similar pain scores after pathway implementation. However, the pre-post-study design has limitations in attributing causality to the pathway itself. Key confounders were not fully accounted for. The clinical significance of the small reduction in length of stay is also questionable.
Conclusions:
This commentary highlights important limitations of the Manning et al. study, including the retrospective design, potential confounding factors, small effect size, and lack of long-term outcomes. While the study provides early evidence for a multidisciplinary opioid reduction approach, further rigorous prospective research is needed to confirm the observed benefits and long-term impacts. Additional focus on direct opioid consumption, equivalent analgesia assessment, and clinically meaningful outcomes is warranted.
